SOURCES
David L. Hoey, president and CEO of Vaxxas, Cambridge, MA, and Brisbane, Australia.
Pablo Penaloza-MacMaster, PhD, assistant professor of microbiology and immunology, Feinberg Faculty of Medication, Northwestern College, Chicago.
Jasdave Chahal, PhD, co-founder and chief scientist, Tiba Biotech, Cambridge, MA, and Brisbane, Australia.
Vaxart information launch: “Vaxart Introduced Constructive High-line Part II medical Examine Knowledge Demonstrating Safaety and Immunogenicity of Its Wuhan S-Solely COVID-19 Tablet Vaccine Candidate.”
Mark Herr, spokesperson, Vaxart Inc.
The Commonwealth Fund: “Two Years of U.S. COVID-19 Vaccines Have Prevented Hundreds of thousands of Hospitalizations and Deaths.”
The Lancet Infectious Illnesses: “International affect of the primary yr of COVID-19 vaccination: a mathematical modelling research.”
CDC: COVID Knowledge Tracker, “Needle Fears and Phobias—Discover Methods to Handle.”
U.S. Specialty Formulations information launch: “Analysis Demonstrates Advantages of Oral COVID-19 Vaccine.”
CanSino Biologics Inc. assertion: “Inside Data.”
Coalition for Epidemic Preparedness Improvements: E-mail assertion; Information releases: “The Race to Future-Proof Coronavirus Vaccines;.” “Coming in from the chilly: needle-free patch expertise for mRNA vaccines goals to finish want for frozen storage and enhance entry.”
Government Workplace of the President: “Assertion of Administration Coverage.”
Science: “Mosaic RBD nanoparticles shield in opposition to problem by numerous sarbecoviruses in animal fashions.”
Caltech information launch: “Nanoparticle Vaccine Protects Towards a Spectrum of COVID-19-causing Variants and Associated Viruses.”
U.S. Authorities Accountability Workplace. “Operation Warp Velocity.”
Bharat Biotech Worldwide Restricted information launch: “Bharat biotech launches iNCOVACC: World’s 1st intranasal COVID vaccine for Main collection and Heterologous booster.”
The Lancet preprints: “Immunogenicity and Tolerability of BBV154 (iNCOVACC®), an Intranasal SARS-CoV-2 Vaccine, In contrast with Intramuscular Covaxin® in Wholesome Adults: A Randomised, Open-Label, Part 3 Scientific Trial.”
Cell: “Intranasal pediatric parainfluenza virus-vectored SARS-CoV-2 vaccine is protecting in monkeys.”
Nationwide Institute of Allergy and Infectious Illnesses information launch: “NIAID Points Additional Awards to Assist Pan-Coronavirus Vaccine Improvement.”
CEPI information launch: “CEPI and DIOSynVax associate in quest to develop broadly protecting Betacoronavirus vaccine.”
CDC: “Understanding How COVID-19 Vaccines Work.”
Nature Immunology: “The T-cell immune response in opposition to SARS-CoV-2.”
Nationwide Institutes of Well being: “T cells shield in opposition to COVID-19 in absence of antibody response.”
PNAS: “Vaccine-induced systemic and mucosal T cell immunity to SARS-CoV-2 viral variants.”
Cell Reviews: “Pre-existing immunity modulates responses to mRNA boosters.”
College of Minnesota Middle for Infectious Illness Analysis and Coverage: “Coronavirus Vaccines R&D Roadmap.”
NIH information launch: “2NIAID Research Spotlight COVID-10 Natal Vaccine Potential.”
U.S. Specialty Formulations information launch: “Analysis demonstrates advantages of oral COVID-19 vaccine.”
